Key Insights

Highlights

Treatment Research

5 treatments under study, led by Ssri Treated Group

Research Leaders

9 sponsors active, led by University of Calgary

Related Conditions

Often studied with 12 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 5 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Not Applicable (2)

Trial Status

Unknown3
Recruiting2

Clinical Trials (5)

Showing 5 of 5 trials
NCT03953014Recruiting

Pharmacogenetics of Antidepressant-Induced Disinhibition

NCT06763081Recruiting

Pharmacogenomics of Selective Serotonin Reuptake Inhibitor (SSRI)-Induced Behavioural Activation

NCT05099913Not ApplicableUnknown

The Role of Neuromodulators in Refractory Functional Dyspepsia

NCT04830241Unknown

Neonatal Hypotonia Associated With in Utero Exposure to Antidepressant

NCT00817011Not ApplicableUnknown

Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness

Showing all 5 trials

Research Network

Common Treatments

  • Ssri Treated Group1
  • Not Applicable Observational Study1
  • Deanxit1
  • Antidepressant1
  • Nonssri Treated Group1

Active Sponsors

  • University of Calgary2
  • Children's Hospital Research Institute of Manitoba1
  • University Hospital, Caen1
  • RenJi Hospital1
  • Samsung Medical Center1

Top Investigators

Related Conditions

  • Anxiety Disorders2
  • Major Depressive Disorder2
  • Depression1
  • Dyspepsia1
  • Neonatal Hypotonia1

Activity Timeline